Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HLX71 in Healthy Adults
NCT04583228Phase 1Completed
- Sponsor
- Hengenix Biotech
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ace2-fc in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Hengenix Biotech. Primary endpoints: Adverse events, serious adverse events and infusion-related reactions at 28 days and Proportion of subjects undergoing Dose-Limiting Toxicity events at 7 days. Started Apr 2021; status: completed.
02
Drugs
ace2-fc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04583228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583228.